Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

2.

Medicaid expansion tied to smaller declines in early-stage cancer detection

3.

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

4.

In myelofibrosis, combinations of rufolitinib reduce spleen volume.

5.

The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot